The anti-p40 drug, ustekinumab, which binds to the p40 subunit common to interleukin-12 and interleukin-23, has also shown considerable improvements in patients with psoriasis, psoriatic arthritis and Crohn’s disease and is currently used for the treatment of these diseases [157]. This evidence concerns the gene IL37 and psoriatic arthritis.